Introduction
============

Patients suffering from acute myocardial infarction (AMI) are at an increased risk for high mortality, particularly in the setting of AMI complicated by cardiogenic shock (CS), although both emergency revascularization (ERV) and thrombolysis have been widely used.[@b1-ppa-10-297] The intra-aortic balloon pump (IABP) has been widely used since it was first used clinically in 1968. It improves diastolic coronary blood flow and reduces both afterload and myocardial oxygen demand,[@b2-ppa-10-297] changes thought to have positive effects on myocardial recovery following AMI.[@b3-ppa-10-297],[@b4-ppa-10-297]

According to the American College of Cardiology and American Heart Association (ACC/AHA 2012) guidelines, IABP was recommended for CS and its insertion was suggested at the completion of coronary angiography and revascularization (IIa).[@b5-ppa-10-297] The European Society of Cardiology guidelines also recommended IABP as a bridge to reperfusion for patients suffering from CS.[@b6-ppa-10-297] In recent years, several large randomized controlled trials (RCTs)[@b7-ppa-10-297]--[@b10-ppa-10-297] and meta-analyses[@b11-ppa-10-297],[@b12-ppa-10-297] have demonstrated only limited or even no benefits with respect to midterm and long-term all-cause mortality in patients with AMI complicated by CS for whom early revascularization was planned. However, two other meta-analyses[@b13-ppa-10-297],[@b14-ppa-10-297] have demonstrated that IABP has a positive impact with respect to all-cause mortality in these patients for whom thrombolysis was used as a preferred reperfusion strategy. These conflicting data challenged the recommendations of the current guidelines and these aforementioned meta-analyses did not include all the available relevant clinical trials. Therefore, we sought to conduct an updated, comprehensive meta-analysis involving as many clinical trials as possible to evaluate the evidence pertaining to the performance of IABP performed as an adjunct therapy in patients suffering from an AMI complicated with CS or not.

Methods
=======

Literature search
-----------------

We searched Medline, EMBASE, and the Cochrane Controlled Trials Registry from their dates of inception until May 2015 for clinical trials comparing outcomes following IABP use with outcomes in the absence of IABP use (defined as the Control group) following AMI. To be certain all relevant studies were included, the electronic databases were searched using combinations of several relevant keywords, including intra-aortic balloon pump, counterpulsation, acute myocardial infarction, and clinical trials. All potentially relevant articles and references from published reviews and meta-analyses were subsequently screened for eligibility.

Inclusion and exclusion criteria
--------------------------------

The articles were required to meet the following criteria: 1) adult patients suffering from AMI (age from 18 to 90 years), regardless of CS and 2) clinical trials comparing an IABP group and a control group. The exclusion criteria were as follows: 1) nonhuman or ongoing studies; 2) non-English language studies; 3) reviews or meta-analyses; 4) duplicated studies or different studies using the sample; and 5) patients supported by other cardiac assist devices.

Data extraction, synthesis, and quality assessment
--------------------------------------------------

Two investigators (FZG and GXF) independently reviewed all relevant articles to assess their eligibility, using standardized data-abstraction forms. Disagreements were resolved by a third investigator (CLW). We extracted the following data from each included study: the name of the trial or first author, publication year, inclusion and exclusion criteria, baseline demographics, and clinical outcomes at the hospital and/or during follow-up. All included studies were divided into two subgroups based on the design of each study, described as RCTs and observational clinical trials (Obs). To account for the effects of treatment, we also grouped the studies by type of reperfusion, as follows: no reperfusion, ERV alone, including either percutaneous transcoronary angioplasty or coronary artery bypass grafting, thrombolytic therapy alone (TT alone), and ERV plus TT. However, the patients with CS were selected as another subgroup to determine whether they responded to IABP insertion. Moreover, the patients with AMI were divided into two subgroups based on whether they underwent IABP insertion before or after reperfusion to determine the best opportunity for IABP insertion. The quality of all retrieved studies was assessed to ensure minimization of bias, but no formal scoring system was used.

Study endpoints
---------------

The primary efficacy endpoint was the rate of all-cause mortality, which was evaluated across three periods based on the follow-up durations of the included trials, including in-hospital mortality, midterm mortality (defined as mortality between 30 days and 2 months), and long-term mortality (defined as mortality after 6 months), and the secondary efficacy endpoints were new heart failure, reinfarction, and recurrent ischemia during hospitalization. The incidences of stroke and severe bleeding requiring blood transfusion in-hospital were evaluated as safety endpoints. The rates of all-cause mortality and new heart failure could be replaced by cardiac death[@b15-ppa-10-297] and pulmonary edema,[@b16-ppa-10-297] respectively, if the included articles did not have the relevant data. The definitions of the clinical endpoints varied slightly among the included trials, and we evaluated the clinical endpoints using standardized definitions.

Statistical analysis
--------------------

All endpoints were treated as dichotomous variables, which were analyzed using odds ratio (OR) with 95% confidence interval (CI). Statistical heterogeneity among the included studies was measured using the Cochrane's Q test and the *I*^2^ statistic. When the *P*-value of Q test was \<0.10 and/or the *I*^2^ was ≥50%, significant heterogeneity was considered and a random-effects model was selected. If not, the fixed-effects model and the Mantel--Haenszel method were used. Publication bias was examined via Egger's test (*P*\<0.1 for significant asymmetry).[@b17-ppa-10-297] To assess the stability of the overall treatment effects, sensitivity analyses (exclude one study at a time) were performed. All *P*-values were two-tailed, and a *P*-value \<0.05 was considered statistically significant. This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statements,[@b18-ppa-10-297] and the data were analyzed using STATA 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Eligible studies and patient characteristics
--------------------------------------------

After screening 1,841 initial articles using the electronic databases, 33 clinical trials were identified, including 15 RCTs (2,497 patients)[@b7-ppa-10-297]--[@b10-ppa-10-297],[@b15-ppa-10-297],[@b19-ppa-10-297]--[@b30-ppa-10-297] and 18 Obs (16,392 patients)[@b16-ppa-10-297],[@b31-ppa-10-297]--[@b49-ppa-10-297] ([Figure 1](#f1-ppa-10-297){ref-type="fig"}). The baseline characteristics of the included RCTs and Obs are summarized in [Tables 1](#t1-ppa-10-297){ref-type="table"}[](#t2-ppa-10-297){ref-type="table"}[](#t3-ppa-10-297){ref-type="table"}--[4](#t4-ppa-10-297){ref-type="table"}.

Primary efficacy endpoint
-------------------------

### In-hospital mortality

As shown in the [Figure 2A](#f2-ppa-10-297){ref-type="fig"}, the overall risk of in-hospital mortality was not reduced significantly following IABP use (OR 0.87, 95% CI: 0.59--1.28, *P*=0.479; *P*\<0.001, *I*^2^=90.6%); similar results were observed for both the RCTs and Obs (RCT: OR 0.89, 95% CI: 0.54--1.49, *P*=0.669; *P*=0.298, *I*^2^=15.7%; Obs: OR 0.84, 95% CI: 0.52--1.35, *P*=0.467; *P*\<0.001, *I*^2^=94.4%). The results of the Egger's test indicted that no publication bias was encountered (*P*=0.406, 0.325, 0.175 for Obs, RCT, and overall, respectively).

### Midterm mortality

The comparison between IABP use and no IABP use demonstrated no significant differences with respect to the risk of midterm mortality (OR 1.12, 95% CI: 0.53--2.38, *P*=0.768; *P*\<0.001, *I*^2^=93.4%; [Figure 2B](#f2-ppa-10-297){ref-type="fig"}), as well as no significant reductions in risk in the RCTs and Obs (RCT: OR 0.84, 95% CI: 0.43--1.64, *P*=0.609; *P*=0.122, *I*^2^=45.0%; Obs: OR 1.18, 95% CI: 0.40--3.47, *P*=0.760; *P*\<0.001, *I*^2^=95.5%). No publication bias was observed based on the results of the Egger's test (*P*=0.135, 0.843, 0.813 for Obs, RCT, and overall, respectively).

### Long-term mortality

A significantly lower incidence of long-term mortality rate was observed in the IABP group compared with the control group (OR 0.66, 95% CI: 0.48--0.91, *P*=0.010; *P*=0.025, *I*^2^=47.4%; [Figure 2C](#f2-ppa-10-297){ref-type="fig"}), without publication bias (Egger's test: *P*=0.132). A similar result was observed in the RCTs (OR 0.71, 95% CI: 0.50--0.99, *P*=0.046; *P*=0.177, *I*^2^=30.2%; Egger's test: *P*=0.191), and no significant difference was observed in Obs (OR 0.60, 95% CI: 0.31--1.19, *P*=0.145; *P*=0.012, *I*^2^=68.9%; Egger's test: *P*=0.359). A sensitivity analysis confirmed the beneficial effects of IABP with respect to the long-term mortality.

Secondary efficacy endpoints
----------------------------

### Reinfarction

The impact of IABP insertion did not significantly differ from no IABP use with respect to the reduction of risk of reinfarction during hospitalization (OR 1.10, 95% CI: 0.68--1.78, *P*=0.706; *P*=0.094, *I*^2^=34.3%; [Figure 3A](#f3-ppa-10-297){ref-type="fig"}), and the results from the RCTs and Obs were similar (Obs: OR 1.25, 95% CI: 0.48--3.25, *P*=0.644; *P*=0.027, *I*^2^=55.6%; RCT: OR 0.91, 95% CI: 0.60--1.40, *P*=0.680; *P*=0.580, *I*^2^=0.0%). No publication bias was observed for reinfarction (Egger's test: *P*=0.548, 0.667, 0.837 for Obs, RCT, and overall, respectively).

### Recurrent ischemia

As depicted in [Figure 3B](#f3-ppa-10-297){ref-type="fig"}, there was no significant difference between IABP use and no IABP use with respect to the risk of in-hospital ischemia recurrence (OR 0.87, 95% CI: 0.36--2.12, *P*=0.754; *P*=0.001, *I*^2^=75.7%), in either the RCTs or Obs (RCT: OR 0.49, 95% CI: 0.18--1.31, *P*=0.155; *P*=0.060, *I*^2^=59.4%; Obs: OR 2.31, 95% CI: 1.20--4.46, *P*=0.013; *P*=0.744, *I*^2^=0.0%). No publication bias was observed (*P*=0.855, 0.836 for RCTs and overall, respectively).

### New heart failure

The overall incidence of new heart failure was similar between the two subgroups (OR 1.40, 95% CI: 0.72--2.72, *P*=0.320; *P*\<0.001, *I*^2^=82.3%; [Figure 3C](#f3-ppa-10-297){ref-type="fig"}), as well as in the RCTs (OR 0.89, 95% CI: 0.63--1.28, *P*=0.541; *P*=0.404, *I*^2^=2.0%), whereas the risk of new heart failure increased significantly in the Obs (OR 3.29, 95% CI: 1.29--8.38, *P*=0.013; *P*=0.005, *I*^2^=87.5%). The results from the Egger's test suggested no publication bias regarding the incidence of new heart failure (*P*=0.875, 0.866 for RCTs and overall, respectively).

Safety endpoints
----------------

### Severe bleeding requiring blood transfusion

The incidence of severe bleeding requiring blood transfusion was higher in the IABP group than in control group (OR 2.05, 95% CI: 1.29--3.25, *P*=0.002; *P*=0.001, *I*^2^=78.5%; [Figure 4A](#f4-ppa-10-297){ref-type="fig"}); a similar result was observed in the Obs (OR 3.48, 95% CI: 2.09--5.79, *P*\<0.001; *P*=0.003, *I*^2^=65.1%), whereas no significant difference was observed in RCTs (OR 1.14, 95% CI: 0.87--1.49, *P*=0.338; *P*=0.804, *I*^2^=0.0%). The Egger's test was not suggestive of publication bias (*P*=0.582, 0.640, 0.880 for Obs, RCTs, and overall, respectively). The sensitivity analysis demonstrated that the inferior effects of IABP insertion in the setting of AMI on severe bleeding requiring blood transfusion were always observed by omitting a single study at a time.

### Stroke

IABP usage was associated with a higher in-hospital incidence of stroke (OR 1.71, 95% CI: 1.04--2.82, *P*=0.035, [Figure 4B](#f4-ppa-10-297){ref-type="fig"}) without any heterogeneity (*P*=0.636, *I*^2^=0.0%), which contrasted with the results of RCTs and Obs (OR 1.70, 95% CI: 0.73--3.97, *P*=0.220; *P*=0.302, *I*^2^=17.3% for RCTs; Obs: OR 1.72, 95% CI: 0.93--3.19, *P*=0.085; *P*=0.704, *I*^2^=0.0% for Obs). No publication bias was noted via Egger's test (*P*=0.662, 0.142, 0.248 for Obs, RCTs, and overall, respectively).

### Subgroup analysis

In the subgroup of patients suffering from AMI complicated by CS, significantly lower risks of in-hospital and long-term mortality associated with IABP use versus no IABP use were noted (OR 0.68, 95% CI: 0.46--0.99, *P*=0.045, [Figure 5A](#f5-ppa-10-297){ref-type="fig"}; OR 0.64, 95% CI: 0.41--0.996; *P*=0.048, [Figure 5B](#f5-ppa-10-297){ref-type="fig"}), but no significant difference compared with midterm mortality was observed (OR 0.86, 95% CI: 0.56--1.35, *P*=0.521).

In the subgroup of reperfusion, the combination of IABP and TT alone resulted in a lower midterm mortality rate (OR 0.42, 95% CI: 0.23--0.76, *P*=0.004, [Figure 5C](#f5-ppa-10-297){ref-type="fig"}), although no significant differences were observed with respect to in-hospital and long-term mortality (in-hospital: OR 0.55, 95% CI: 0.21--1.39, *P*=0.206; long-term: OR 0.57, 95% CI: 0.28--1.17, *P*=0.128). Moreover, the combination of IABP and ERV alone was associated with a lower long-term mortality (OR 0.71, 95% CI: 0.49--1.03, *P*=0.072).

In the analysis pertaining to the opportunity for IABP insertion, a reduced risk of long-term mortality was observed among the patients suffering AMI for whom IABP was inserted before reperfusion compared with no IABP use (OR 0.49, 95% CI: 0.34--0.71, *P*\<0.001, [Figure 5D](#f5-ppa-10-297){ref-type="fig"}), although no significant difference was observed between no IABP use and IABP insertion after reperfusion (OR 0.90, 95% CI: 0.35--2.31, *P*=0.825).

Discussion
==========

The major finding of this comprehensive meta-analysis was that IABP insertion was associated with reduced long-term mortality in patients suffering from AMI compared with no IABP use at the cost of potential high risk of stroke and severe bleeding requiring blood transfusion. The subgroup analyses demonstrated that IABP insertion before reperfusion may be an optimal treatment for patients suffering from AMI complicated by CS or patients receiving TT.

Since IABP was first reported for clinical application in 1968,[@b4-ppa-10-297] it has been widely used in patients suffering from AMI, particularly patients following AMI complicated by CS.[@b2-ppa-10-297],[@b50-ppa-10-297] Both the ACC/AHA (2012)[@b5-ppa-10-297] and the European Society of Cardiology guidelines[@b6-ppa-10-297] strongly recommended IABP as a bridge to reperfusion for patients suffering from AMI complicated by CS, recommendations derived from several observational clinical trials.[@b31-ppa-10-297],[@b34-ppa-10-297],[@b39-ppa-10-297] However, these recommendations have been challenged because of several recent meta-analyses[@b12-ppa-10-297] and RCTs,[@b7-ppa-10-297]--[@b10-ppa-10-297],[@b19-ppa-10-297] which demonstrated that IABP for patients with AMI complicated by CS was not associated with reduced mortality, but with high potential risks of major bleeding and stroke. The IABP-SHOCK II trial, a randomized, open-label, multicenter trial involving 600 patients with CS following AMI who underwent early revascularization, demonstrated that IABP did not increase either 6- or 12-month survival rates compared with no IABP use.[@b7-ppa-10-297],[@b8-ppa-10-297] Moreover, the IABP SHOCK trial[@b28-ppa-10-297] demonstrated that IABP insertion exerted only modest or even no effects on the acute physiology and chronic health evaluation II score as a marker of disease severity, improvements in cardiac index, reduced inflammation, or reduced plasma brain natriuretic peptide levels compared with medical therapy alone. In summary, the current data did not support IABP as a routine treatment for patients with AMI regardless of whether the patients suffered from AMI complicated by CS, which called the above-mentioned guidelines into question. On the other hand, all these over-mentioned meta-analyses for IABP application did not include all available relevant citations and there was none of them grouped meticulously which might cover the beneficial efficacy of IABP on special patients. Therefore, we carried out this updated, comprehensive meta-analysis to explore which patients could benefit mostly from IABP insertion.

In spite of the advances in early revascularization,[@b28-ppa-10-297] the mortality rate of patients suffering from AMI complicated by CS remains high; IABP was empirically preferred with respect to the treatment of these patients. The thrombolysis and counterpulsation to improve survival in myocardial infarction (TACTICS) trial[@b19-ppa-10-297] demonstrated that IABP insertion for patients with AMI complicated by either hypotension or severe heart failure who were receiving thrombolysis was not associated with a significant risk reduction on 6-month mortality, but was associated with increased survival rates for patients in Killip classes III or IV (39% for combined therapy versus 80% for fibrinolysis alone). The data from the present study demonstrated the superior effects of IABP in patients suffering from AMI, particularly those complicated with CS, findings consistent with results of two previous meta-analyses.[@b13-ppa-10-297],[@b14-ppa-10-297] IABP may be the optimal choice for specific patients with AMI, but not for all patients with AMI.

In fact, the observed reductions in mortality secondary to IABP usage may be balanced by the increased rates of stroke and severe bleeding. More and more evidence, including the results from our study, has demonstrated that IABP insertion is associated with a higher incidence of severe bleeding and stroke. Four risk factors for complications following IABP insertion were identified from the Benchmark Registry:[@b51-ppa-10-297] age ≥75 years, female sex, peripheral arterial disease, and body surface area \<1.65 m^2^. In the meta-analysis published by Sjauw et al,[@b13-ppa-10-297] a significantly increased rate of stroke secondary to IABP use was observed in patients suffering from AMI. Restricting activity due to IABP insertion for long periods may promote the development of venous thrombosis, resulting in an increased risk of all-cause death among affected patients. Moreover, several studies[@b52-ppa-10-297],[@b53-ppa-10-297] have demonstrated that major bleeding was associated with an increased risk of death, indicating that bleeding was dangerous not only because of the hemorrhaging itself but also because it forced the discontinuation of the IABP and necessary antiplatelet therapy, resulting in higher rates of thrombotic events. Thiele et al[@b7-ppa-10-297],[@b8-ppa-10-297] pointed out that the higher in-hospital mortality in the AMI patients complicated with CS might depend on hemodynamic deterioration, multiorgan dysfunction, or systemic inflammatory response syndrome. One more possible related point was that some of the included patients were too serious to receive the implantation of IABP before their deaths or even had no access to implant this equipment in time if they were initially treated in a peripheral center. In contrast, the lower long-term mortality among these patients might be due to the successful insertion of IABP which positively affected myocardial recovery following AMI. Therefore, it may be more useful to determine which patients benefit most from IABP insertion, as opposed to studying the complications of IABP use.

In contrast to the recommendations of the ACC/AHA (2012) guidelines, the SHOCK trial[@b28-ppa-10-297] demonstrated that a higher rate of in-hospital mortality was observed among the patients suffering from AMI complicated by CS associated with IABP insertion following reperfusion compared with no IABP use (36.8% vs 28.6%). However, the balloon pump-assisted coronary intervention study (BCIS-1) trial[@b10-ppa-10-297] demonstrated that IABP insertion before reperfusion may result in a significantly reduced risk of long-term mortality among these patients. Therefore, a subgroup analysis was conducted in our study to address this controversy and determine the ideal opportunity for IABP insertion, as well as which patients may benefit most from IABP insertion. IABP usage was associated with a lower risk of mortality when inserted before reperfusion, a finding consistent with those of previous studies.[@b10-ppa-10-297],[@b27-ppa-10-297] Early IABP insertion promoted hemodynamic stability and reduced myocardial oxygen demand, which may be important in patients suffering from AMI complicated by CS.[@b2-ppa-10-297] Our results indicated that IABP insertion was associated with feasible benefits with respect to long-term survival in patients with AMI, particularly patients suffering from AMI complicated by CS and patients receiving thrombolytic therapy.

Several questions remained unanswered. First, there were not enough data to assess the optimal duration of IABP insertion for patients without severe complications, as well as for which patients the IABP may be removed at an earlier time. Most of current literature regarding the efficacy of IABP use consented to a duration of \~48 hours, although no absolute benefits regarding survival rates were demonstrated. A second dilemma involved the ideal opportunity for IABP insertion in patients with AMI complicated by hemodynamic compromise. The ACC/AHA (2012) guidelines recommend implantation at the completion of reperfusion.[@b5-ppa-10-297] Third, divergence regarding specifics about the reperfusion strategies was observed. Both ERV alone and TT alone demonstrated potential benefits in patients with AMI in this meta-analysis. Therefore, powerful randomized clinical trials comparing IABP use and no IABP use in patients suffering from AMI complicated by CS focusing on the optimal duration of IABP, most suitable time for IABP insertion, and more precise reperfusion strategies must be performed to guide clinical decision making.

Limitations
===========

This study had several limitations. First, this meta-analysis was not based on individual patient data, and the small sample size of several included RCTs also made the evaluation of IABP's efficacy easily influenced. Second, different studies used different endpoint definitions, which may have been the source of bias. Third, the lack of other potential confounding factors, such as the time of IABP insertion, duration of IABP placement, insertion details, including technology and choice of sheath with different sizes, as well as reperfusion strategies, did not allow us to explore the effects of IABP on patients with AMI or the underlying mechanisms of these effects. Additionally, there was no uniform or clear follow-up period.

Conclusion
==========

IABP insertion is associated with feasible benefits with respect to long-term survival in patients with AMI, particularly those suffering from CS and receiving thrombolytic therapy, at the cost of higher risk of severe bleeding and stroke.

The study was supported by the Jiangsu Provincial Special Program of Medical Science (BL2013001).

**Author contributions**

Z-GF and X-FG were involved in the design, literature searching, assessment of study quality, and drafted the manuscript. Disagreements were resolved by L-WC. X-BL and M-XS revised critically the manuscript. Z-GF and X-FG performed statistical analysis and critically revised the manuscript. QJ, HZ, and Y-ZR constructed the maps. S-LC and N-LT critically revised original study design and the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.
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###### 

Forest plots of the primary efficacy endpoint of the included trials.

**Notes:** The odds ratio (OR) of in-hospital all-cause mortality (**A**), midterm all-cause mortality (**B**), and long-term all-cause mortality (**C**), associated with IABP use compared with no IABP use, stratified by different dual regimens. Weights are from random effects analysis.

**Abbreviations:** CI, confidence interval; IABP, intra-aortic balloon pump; RCT, randomized controlled trial; ID, identification.
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###### 

Forest plots of the secondary efficacy endpoint of the included trials.

**Notes:** The odds ratio (OR) of reinfarction (**A**), recurrent ischemia (**B**), and new heart failure (**C**) associated with IABP use versus no IABP use stratified by different dual regimens. Weights are from random effects analysis.

**Abbreviations:** CI, confidence interval; IABP, intra-aortic balloon pump; RCT, randomized controlled trial; ID, identification.
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![Forest plots of the safety endpoints of the included trials.\
**Notes:** The odds ratio (OR) of severe bleeding requiring blood transfusion (**A**) and stroke (**B**) associated with IABP use versus no IABP use stratified by different dual regimens. Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; IABP, intra-aortic balloon pump; RCT, randomized controlled trial; ID, identification.](ppa-10-297Fig4){#f4-ppa-10-297}

###### 

Forest plots of the subgroup analysis of the included trials.

**Notes:** The odds ratio (OR) of in-hospital all-cause mortality (**A**) and long-term all-cause mortality (**B**) among the patients suffering from AMI complicated by CS, as well as midterm all-cause mortality (**C**) and the long-term mortality associated with different opportunities of IABP insertion vs no IABP use (**D**) according to reperfusion strategy and IABP insertion associated with IABP use versus no IABP use stratified by different dual regimens. (**C**) \#: Different groups of patients from the TACTICS trial received the corresponding reperfusion; \#\#: different groups of patients from the GUSTO-I trial received the corresponding reperfusion. Weights are from random effects analysis.

**Abbreviations:** AMI, acute myocardial infarction; CI, confidence interval; ERV, emergency revascularization; TT, thrombolytic therapy; CS, cardiogenic shock; IABP, intra-aortic balloon pump; ID, identification; NA, not available.
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###### 

The characteristics of randomized controlled trials pertaining to the use of an intra-aortic balloon pump in the setting of AMI

  Study                                            Publication year   Type of reperfusion for AMI   Inclusion criteria                  Excluded CS   Follow-up duration (d)
  ------------------------------------------------ ------------------ ----------------------------- ----------------------------------- ------------- ------------------------
  Waksman et al[@b20-ppa-10-297]                   1993               Thrombolysis                  AMI with CS                         No            360
  TACTICS[@b19-ppa-10-297]                         2005               Thrombolysis, RV              AMI with hypotension or severe HF   No            30, 180
  Li et al[@b27-ppa-10-297]                        2007               RV                            AMI with CS                         No            360
  SHOCK Trial[@b28-ppa-10-297]                     2010               ERV                           AMI with CS                         No            In-hospital
  IABP-SHOCK II[@b7-ppa-10-297],[@b8-ppa-10-297]   2013               ERV                           AMI with CS                         No            30, 360
  O'Rourke et al[@b22-ppa-10-297]                  1981               No reperfusion                AMI with acute HF                   NA            450
  Flaherty et al[@b15-ppa-10-297]                  1985               No reperfusion                AMI without CS                      Yes           14, 60
  Ohman et al[@b21-ppa-10-297]                     1994               ERV                           AMI without CS                      Yes           In-hospital
  Kono et al[@b23-ppa-10-297]                      1996               Failed thrombolysis           AMI without CS                      Yes           30
  PAMI-II[@b24-ppa-10-297]                         1997               ERV                           AMI without CS                      Yes           In-hospital
  Vijayalakshmi et al[@b26-ppa-10-297]             2007               ERV                           AMI without CS                      Yes           30
  Gu et al[@b29-ppa-10-297]                        2011               ERV                           AMI without CS                      Yes           30, 180
  CRISP AMI[@b30-ppa-10-297]                       2011               ERV                           AMI without CS                      Yes           30, 180
  BCIS-1[@b10-ppa-10-297]                          2013               ERV                           AMI without CS                      Yes           1,530
  Van't Hof et al[@b25-ppa-10-297]                 1999               ERV                           AMI with ST↑/↓\>20 mm               NA            180

**Abbreviations:** AMI, acute myocardial infarction; CS, cardiogenic shock; d, days; ERV, emergency revascularization; HF, heart failure; NA, not available; RV, revascularization, including percutaneous transcoronary angioplasty and coronary artery bypass grafting; ST, ST-segments.

###### 

The characteristics of observational trials pertaining to the use of an intra-aortic balloon pump in the setting of AMI

  Study                                   Publication year   Type of reperfusion for AMI   Inclusion criteria      Excluded CS   Follow-up duration (d)
  --------------------------------------- ------------------ ----------------------------- ----------------------- ------------- ------------------------
  Moulopoulos et al[@b31-ppa-10-297]      1986               No reperfusion                AMI with CS             No            In-hospital
  Bengtson et al[@b32-ppa-10-297]         1992               NA                            AMI with CS             No            In-hospital
  Stomel et al[@b33-ppa-10-297]           1994               Thrombolysis, ERV             AMI with CS             No            In-hospital
  Kovack et al[@b35-ppa-10-297]           1997               Thrombolysis                  AMI with CS             No            30, 360
  GUSTO-I[@b34-ppa-10-297]                1997               Thrombolysis, RV              AMI with CS             No            30, 360
  SHOCK Trial Registry[@b38-ppa-10-297]   2000               Thrombolysis, ERV             AMI with suspected CS   No            In-hospital
  NRMI-2[@b39-ppa-10-297]                 2001               Thrombolysis, ERV             AMI with CS             No            In-hospital
  French et al[@b40-ppa-10-297]           2003               Thrombolysis, ERV             AMI with CS             No            360
  Gu et al[@b41-ppa-10-297]               2010               ERV                           AMI with CS             No            30, 180
  Stub et al[@b43-ppa-10-297]             2011               RV                            ACS with CS             No            30
  EHS PCI Registry[@b42-ppa-10-297]       2011               ERV                           AMI with CS             No            In-hospital
  AMC CS[@b49-ppa-10-297]                 2012               ERV                           AMI with CS             No            30
  ALKK-PCI Registry[@b45-ppa-10-297]      2013               ERV                           AMI with CS             No            In-hospital
  Dziewierz et al[@b46-ppa-10-297]        2014               ERV                           AMI with CS             No            30, 360
  Ohman et al[@b16-ppa-10-297]            1991               Thrombolysis                  AMI without CS          Yes           In-hospital
  Mahmoudi et al[@b44-ppa-10-297]         2012               ERV                           AMI without CS          Yes           In-hospital
  Brodie et al[@b36-ppa-10-297]           1999               ERV                           AMI without prior TT    NA            30
  Kumbasar et al[@b37-ppa-10-297]         1999               Thrombolysis                  AMI ≤6 h                NA            In-hospital

**Abbreviations:** AMI, acute myocardial infarction; CS, cardiogenic shock; d, days; ERV, emergency revascularization; h, hours; NA, not available; RV, revascularization, including percutaneous transcoronary angioplasty and coronary artery bypass grafting; TT, thrombolytic therapy.

###### 

The baseline characteristics of randomized controlled trials pertaining to the use of an IABP in the setting of AMI

  Study                                      Patients, N (IABP/control)   Mean age, years (IABP/control)                                                                    Male, n (IABP/control)   Hypertension, n (IABP/control)   Diabetes, n (IABP/control)   Prior MI, n (IABP/control)
  ------------------------------------------ ---------------------------- ------------------------------------------------------------------------------------------------- ------------------------ -------------------------------- ---------------------------- ----------------------------
  Waksman et al[@b20-ppa-10-297]             24/21                        66.8/67.8                                                                                         14/15                    14/10                            NA/NA                        15/11
  TACTICS[@b19-ppa-10-297]                   30/27                        68[\*](#tfn3-ppa-10-297){ref-type="table-fn"}/67[\*](#tfn3-ppa-10-297){ref-type="table-fn"}       23/20                    NA/NA                            9/3                          12/5
  Li et al[@b27-ppa-10-297]                  20/19                        67.4/64.9                                                                                         12/12                    NA/NA                            9/8                          NA/NA
  SHOCK Trial[@b28-ppa-10-297]               19/21                        62.1/66.1                                                                                         14/17                    8/10                             10/10                        4/5
  IABP-SHOCK II[@b8-ppa-10-297]              299/296                      70[\*](#tfn3-ppa-10-297){ref-type="table-fn"}/69[\*](#tfn3-ppa-10-297){ref-type="table-fn"}       202/211                  213/199                          105/90                       71/61
  O'Rourke et al[@b22-ppa-10-297]            14/16                        60/54                                                                                             12/12                    NA/NA                            NA/NA                        2/5
  Flaherty et al[@b15-ppa-10-297]            10/10                        52/53                                                                                             9/8                      NA/NA                            NA/NA                        4/4
  Ohman et al[@b21-ppa-10-297]               96/86                        56/55                                                                                             71/65                    47/37                            16/15                        19/20
  Kono et al[@b23-ppa-10-297]                23/22                        54/60                                                                                             20/16                    10/13                            6/6                          NA/NA
  PAMI-II[@b24-ppa-10-297]                   211/226                      64.7/63.7                                                                                         158/170                  116/126                          45/33                        45/49
  Vijayalakshmi et al[@b26-ppa-10-297]       17/16                        57.5/59                                                                                           14/14                    6/6                              3/4                          2/4
  Gu et al[@b29-ppa-10-297]                  51/55                        67.4/66.6                                                                                         29/36                    35/33                            18/19                        2/3
  CRISP AMI[@b30-ppa-10-297]                 156/173                      56.1[\*](#tfn3-ppa-10-297){ref-type="table-fn"}/57.7[\*](#tfn3-ppa-10-297){ref-type="table-fn"}   132/144                  39/60                            27/36                        0/0
  BCIS-1[@b9-ppa-10-297],[@b10-ppa-10-297]   151/150                      71/71                                                                                             122/117                  95/91                            56/50                        113/108
  Van't Hof et al[@b25-ppa-10-297]           118/120                      59/56                                                                                             99/101                   NA/NA                            12/9                         17/16

**Note:**

Median.

**Abbreviations:** AMI, acute myocardial infarction; IABP, intra-aortic balloon pump; MI, myocardial infarction; NA, not available.

###### 

The baseline characteristics of observational clinical trials pertaining to the use of an IABP in the setting of AMI

  Study                                Patients, N (IABP/control)   Mean age, years (IABP/control)                                                                  Male, n (IABP/control)   Hypertension, n (IABP/control)   Diabetes, n (IABP/control)   Prior MI, n (IABP/control)
  ------------------------------------ ---------------------------- ----------------------------------------------------------------------------------------------- ------------------------ -------------------------------- ---------------------------- ----------------------------
  Moulopoulos et al[@b31-ppa-10-297]   35/14                        60.3/61.1                                                                                       29/13                    NA/NA                            NA/NA                        6/16
  Bengtson et al[@b32-ppa-10-297]      99/101                       64/67                                                                                           NA/NA                    NA/NA                            NA/NA                        NA/NA
  Stomel et al[@b33-ppa-10-297]        51/13                        66/66                                                                                           23/8                     31/6                             11/3                         16/2
  Kovack et al[@b35-ppa-10-297]        27/19                        62/64                                                                                           16/12                    10/11                            7/5                          6/1
  GUSTO-I[@b34-ppa-10-297]             62/248                       64[\*](#tfn5-ppa-10-297){ref-type="table-fn"}/68[\*](#tfn5-ppa-10-297){ref-type="table-fn"}     42/154                   23/99                            14/57                        19/67
  Shock Registry[@b38-ppa-10-297]      439/417                      65.2/73.4                                                                                       294/250                  203/233                          137/141                      154/188
  NRMI-2[@b39-ppa-10-297]              4,215/4,456                  \~67/74.1                                                                                       \~60.5%/50.5%            \~47%/49%                        \~29%/32%                    \~26%/30%
  French et al[@b40-ppa-10-297]        260/41                       65.3/67.4                                                                                       175/30                   124/17                           83/10                        84/14
  Gu et al[@b41-ppa-10-297]            43/48                        70.4/67.9                                                                                       27/31                    30/32                            17/17                        NA/NA
  Stub et al[@b43-ppa-10-297]          251/159                      65.7/67.7                                                                                       189/110                  142/99                           71/39                        54/38
  EHS PCI Registry[@b42-ppa-10-297]    162/491                      65.3/65.4                                                                                       110/335                  95/316                           44/138                       58/136
  AMC CS[@b49-ppa-10-297]              199/93                       64.7/61.5                                                                                       136/61                   69/29                            36/16                        60/22
  ALKK-PCI Registry[@b45-ppa-10-297]   487/1,426                    67.7/69.9                                                                                       372/970                  359/1,084                        159/462                      171/549
  Dziewierz et al[@b46-ppa-10-297]     30/21                        64.5[\*](#tfn5-ppa-10-297){ref-type="table-fn"}/72[\*](#tfn5-ppa-10-297){ref-type="table-fn"}   25/8                     NA/NA                            8/1                          8/4
  Ohman et al[@b16-ppa-10-297]         85/725                       58/56                                                                                           69/580                   40/297                           17/102                       21/87
  Mahmoudi et al[@b44-ppa-10-297]      70/70                        \~59/60.6                                                                                       \~71.4%/69.2%            \~73.9%/80%                      \~21.9%/27%                  \~12.4%/9.6%
  Brodie et al[@b36-ppa-10-297]        213/1,277                    NA/NA                                                                                           126/916                  NA/NA                            23/85                        56/229
  Kumbasar et al[@b37-ppa-10-297]      25/20                        53.4/53.5                                                                                       22/17                    9/10                             10/5                         NA/NA

**Note:**

Median.

**Abbreviations:** AMI, acute myocardial infarction; IABP, intra-aortic balloon pump; MI, myocardial infarction; NA, not available.

[^1]: These authors contributed equally to this work
